Alembic Pharma Receives USFDA Final Approval for Valganciclovir Oral Solution
Alembic Pharmaceuticals Ltd 路 Press Release 路 27 Oct 2026, 8:59 pm
Alembic Pharma Receives USFDA Final Approval for Valganciclovir Oral Solution Alembic Pharmaceuticals secured final USFDA approval for its ANDA for Valganciclovir for Oral Solution, 50 mg/mL, on 27th Oct'26. The product is therapeutically equivalent to the RLD, Valcyte for Oral Solution (50 mg/mL) by CHEPLAPHARM Arzneimittel GmbH. The drug is indicated for treating CMV retinitis in AIDS patients and preventing CMV disease in high-risk kidney, heart, or kidney-pancreas transplant recipients. With this clearance, Alembic's cumulative USFDA approvals reach 247 ANDAs, comprising 227 final approvals and 20 tentative approvals.
Original exchange filing (PDF)
More announcements from Alembic Pharmaceuticals Ltd
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Binimetinib Tablets, 15 mg and 45 mg. 路 15 Nov 2026
- Please find attached herewith the Transcript of Post Results Conference Call held on 4th November, 2026. 路 10 Nov 2026
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). 路 05 Nov 2026
- Please find attached Audio Recording of Investor Call. 路 05 Nov 2026
- Please find attached intimation under Regulation 30(5) of SEBI (LODR) Regulations, 2015. 路 04 Nov 2026
- Please find attached Press Release 路 04 Nov 2026
- Please find attached Investor Presentation for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
- Please find attached Press Release for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
